The manufacturing upgrades increase NatureWorks` responsiveness to rapidly evolving market dynamics and high demand for Ingeo™ (PLA) biomaterials.
the world's leading manufacturer of low-carbon PLA biomaterials, today announced a slate of manufacturing technology projects, including lactide monomer purification efficiency, that will increase the availability of the full Ingeo™ (PLA) biomaterials portfolio by 10 percent. Installation is currently underway at NatureWorks' facility in Blair, Nebraska, the world's first and largest commercial-scale PLA manufacturing plant. The projects will be completed by the end of 2021.
The expanded availability will support growth in markets that demand sustainable, low-carbon materials and require the high-performance attributes that Ingeo is uniquely suited to deliver. These markets include 3D printing and nonwoven hygiene masks as well as compostable coffee capsules, teabags, and coated-paper food serviceware.
"The market continues to rapidly evolve due to the COVID-19 pandemic as well as the undiminished demand for sustainable, bio-based alternatives to petrochemical-based plastics," said Rich Altice, President & CEO of NatureWorks. "For NatureWorks to satisfy this unprecedented demand, this purification technology is one of many additional capital improvements we are actively working on at our facility in Blair. At the same time, we continue to pursue a potential future second manufacturing site outside the US to serve our growing international markets."
Ingeo polylactic acid is made in a multi-step process that begins with using annually renewable plants to turn greenhouse gases like carbon dioxide into long-chain sugar molecules. Dextrose, derived from the plant sugar molecules, is fermented into lactic acid that then undergoes a proprietary two-step process to transform it into lactide, the monomer for Ingeo polylactic acid polymer.